Skip to main content
Equibles
BRNS logo

BRNS · Barinthus Biotherapeutics plc.

Track BRNS — free

Use BRNS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BRNS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.74 -0.02 (-2.49%) At close · Sep 8
Rebalance outlook locked
Market Cap
$30.23M
Shares
40.85M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.74 Open$0.74 Day$0.64–0.77 52W close$0.54–1.58 Avg vol 30d71K Short int13K · 0.0% float · 1.0d Short vol54% Last earningsMay 7, 2025 DataApr 2021–Sep 2026 Filing10-Q · Aug 6

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$41.76M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-87.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-39.1%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +18%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 19%
mid-range
Momentum
relative strength
Strong
1-month return +32%
trailing
6-month return +9%
trailing
YTD return +6%
this year
Relative strength −5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.03% of float · ▲ +46.2% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
15 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −6%
Y/Y
Free cash flow $-48.0M
Quant / Vol
risk profile
Very High
Volatility 79%
annualized · 1-yr
Max drawdown −66%
past year
ATR 8.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+18% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
19% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.03% of float · ▲ +46.2% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 19% Range high $2
vs 200-day avg +12% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BRNS
Barinthus Biotherapeutics plc.
this stock
$30.23M +5.7% -100.0% — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
15
% held
22.5%
Net QoQ
-93.8K sh
Top holder
M&G PLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
13.2K
Days to cover
1.0d
Change
+4.2K sh
View
Short Volume
Short vol %
54%
As of
Sep 8, 2026
Short Total
View
Fails to Deliver
FTD shares
2.6K
Value
$1.5K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
48.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-66.4M
EPS diluted
$-1.64
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 9, 2026
This year
16
View
Earnings & Events
Earnings Calls
Last call
May 7, 2025
View
Investor Relations
Latest news
Barinthus Bio Reports Second Quar…
Published
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
BRNS +6.2% +31.7% +8.8% +6.2% +5.7%
SPY -0.1% -0.9% +14.2% -0.1% +12.3%
vs SPY +6.3% +32.6% -5.4% +6.3% -6.6%
Key facts CIK 1828185 CUSIP 91864C107 13F (30d) 6 filings 6 filers Visit website Investor relations